News
-
BioMarin Announces IND For BMN-111 For Achondroplasia Is Active
1/4/2012
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active. The company expects to initiate the Phase 1 trial in the first quarter of 2012.
-
Clinical Hold Removed For Helix Biopharma Corp.'s Topical Interferon Alpha-2B Phase II/III Efficacy Trial IND Application
11/14/2011
Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that the “clinical hold” on its investigational new drug (“IND”) application for its Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial has been removed by the United States Food and Drug Administration (“FDA”).
This website uses cookies to ensure you get the best experience on our website. Learn more